(EET Biobank) NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank

项目摘要 生物病理学中心(BPC)，阿比盖尔·韦克斯纳全国儿童研究所的一部分 医院，设有实验治疗临床试验网络(ETCTN)生物库(Biobank)。 在这个项目中，ETCTN生物库将扩大到包括其他由国家癌症研究所(NCI)支持的项目 早期和试验性试验网络和调查人员，并被称为早期和 实验临床试验(EET)生物库。NCI支持临床试验基础设施，以促进早期 抗癌治疗药物的发展阶段和评价。EET生物库将促进 通过采购、加工、储存和分配高素质的人来收集标准化的生物检疫品 参与NCI 0、I、II期试验和其他实验的癌症患者的生物样品 癌症治疗试验。 EET临床试验将包括一系列癌症类型(即乳腺癌、肺癌、结肠癌、前列腺癌、白血病、黑色素瘤、 淋巴瘤和多发性骨髓瘤)。这些生物样品将链接到与生物样品相关的详细数据 (包括手术、病理和放射学报告的信息)，以及全面的临床 数据，包括详细的药物信息、治疗历史/结果和癌症复发数据。《EET》 生物库将与研究小组和调查人员密切合作，以确保处理生物检疫 对于计划和未来的研究是合适的。在这些努力中，EET生物库将继续支持 向癌症免疫监测和分析中心加工、储存和分发生物检疫试剂 (CIMAC)。生物素将首先分发给研究人员，进行计划中的研究，以满足 目的：纳入临床试验。在达到临床试验的目标后，EET生物库将 为癌症治疗评估批准的项目向合格的研究人员分发生物检疫药物 计划(CTEP)。 EET生物库寻求通过高质量的临床数据库来促进杰出的研究 注解的、与癌症相关的人类生物标本。为了支持这一努力，EET生物库将管理这些 基于当前最佳实践的严格指南和标准操作程序下的生物检疫 生物库、当前的监管指南和最新的实验室技术。EET生物库将 受益于BPC为NCI资助的几个团体支持生物库努力的经验，包括 儿童肿瘤学小组[原西南肿瘤小组] 肿瘤学)和ETCTN。再加上对质量和运营完整性的坚定承诺， EET生物库将是唯一能够提供准确有效的高质量肿瘤和 具有相关临床和流行病学信息的正常样本。

Project Summary The Biopathology Center (BPC), part of the Abigail Wexner Research Institute of Nationwide Children’s Hospital, houses the Experimental Therapeutics Clinical Trials Network (ETCTN) Biospecimen Bank (Biobank). In this project, the ETCTN Biobank will expand to include other National Cancer Institute (NCI)-supported early-phase and experimental trial networks and investigators and be known as the Early-Phase and Experimental Clinical Trials (EET) Biobank. The NCI supports a clinical trials infrastructure to facilitate the early stages of development and evaluation of anti-cancer therapeutic agents. The EET Biobank will promote a collection of standardized biospecimens by procuring, processing, banking, and distributing high-quality human biospecimens from cancer patients who participate in NCI Phases 0, I, and II trials and other experimental therapeutic cancer trials. EET clinical trials will include a range of cancer types (i.e., breast, lung, colon, prostate, leukemia, melanoma, lymphoma, and multiple myeloma). These biospecimens will be linked to detailed biospecimen-related data (including information on surgical, pathological, and radiological reports), as well as comprehensive clinical data, including detailed drug information, treatment histories/outcomes, and cancer recurrence data. The EET Biobank will work closely with study teams and investigators to ensure that biospecimens are handled appropriately for planned and future research. In these efforts, the EET Biobank will continue to support the processing, banking, and distribution of biospecimens to the Cancer Immune Monitoring and Analysis Centers (CIMACs). Biospecimens will first be distributed to investigators for planned research designed to meet the objectives included in the clinical trial. After the objectives in the clinical trial are met, the EET Biobank will then distribute biospecimens to qualified investigators for projects approved by the Cancer Therapy Evaluation Program (CTEP). The EET Biobank seeks to promote outstanding research through the banking of high-quality, clinically annotated, cancer-related human biospecimens. To support this effort, the EET Biobank will manage these biospecimens under strict guidelines and standard operating procedures based on current best practices for biorepositories, current regulatory guidelines, and the latest laboratory technologies. The EET Biobank will benefit from the BPC’s experience in supporting biobanking efforts for several NCI-funded groups, including the NCTN (Children’s Oncology Group [COG], SWOG [formerly the Southwest Oncology Group], NRG Oncology) and the ETCTN. Coupled with a firm commitment to quality and to the integrity of its operations, the EET Biobank will be uniquely able to provide an accurate and effective resource of high-quality tumor and normal samples with associated clinical and epidemiologic information.